melatonin in patients with COVID-19

Phase 3

Conditions: U07.2
COVID-19 disease.
COVID-19, virus not identified

Registration Number: IRCT20200506047323N7

Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 60

Inclusion Criteria

Definitive diagnosis of COVID-19 based on RT-PCR or/and serological testing,
Age >20 years.
Diagnosis of pneumonia based on pulmonary CT-Scan.
Admitted in the intensive care unit.
Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm.

Exclusion Criteria

Patients with underlying disorder, including convulsive disorders, hepatic disease and disorder, renal disease and disorder.
Intubated patients and use of mechanical ventilation.
pregnancy and breastfeeding.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Arterial blood gas (ABG). Timepoint: Before intervention and daily during the intervention. Method of measurement: Biochemical laboratory.;C-Reactive Protein (C-RP). Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: C-RP kit.;Ferritin. Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: Biochemical laboratory.;Lactate dehydrogenase (LDH). Timepoint: Before intervention and 3, 5, 7 days after the start of the intervention. Method of measurement: Biochemical laboratory.

Secondary Outcome Measures

Name	Time	Method
eed for mechanical ventilation. Timepoint: Daily. Method of measurement: Checklist.;Patients consciousness level. Timepoint: Daily. Method of measurement: Glasgow Coma Scale (GCS).;Mortality rate. Timepoint: Daily. Method of measurement: Checklist.